Mindy Kim Graham

Mindy Kim Graham

Auto-generated profile, based on publicly available information

Mindy Kim Graham

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PCPaloma Cejas
Paloma Cejas
Yotam DrierYotam Drier
Yotam Drier
KDKoen M.A. Dreijerink
Koen M.A. Dreijerink
LBLodewijk A. A. Brosens
Lodewijk A. A. Brosens
VDVikram Deshpande
Vikram Deshpande
RSRamesh A. Shivdasani
Ramesh A. Shivdasani

4 July 2017 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
MGMindy Kim Graham
Mindy Kim Graham
AMAlan Meeker
Alan Meeker

18 September 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JBJacqueline A Brosnan-Cashman
Jacqueline A Brosnan-Cashman
MYMing Yuan
Ming Yuan
MGMindy K Graham
Mindy K Graham
ARAnthony J Rizzo
Anthony J Rizzo
KMKaylar M Myers
Kaylar M Myers
AMAlan K Meeker
Alan K Meeker
Cancers must maintain their telomeres at lengths sufficient for cell survival. In several cancer subtypes, a recombination-like mechanism termed alternative lengthening of telomeres (ALT), is frequently used for telomere length maintenance. Cancers utilizing ALT often have lost functional ATRX, a chromatin remodeling protein, through mutation or deletion, thereby strongly implicating ATRX as an ALT suppressor. Herein, we have generated functional ATRX knockouts in four telomerase-positive, ALT-negative human glioma cell lines: MOG-G-UVW, SF188, U-251 and UW479. After loss of ATRX, two of the four cell lines (U-251 and UW479) show multiple characteristics of ALT-positive cells, including ultrabright telomeric DNA foci, ALT-associated PML bodies, and c-circles. However, telomerase activity and overall telomere length heterogeneity are unaffected after ATRX loss, regardless of cellular context. The two cell lines that showed ALT hallmarks after complete ATRX loss also did so upon ATRX depletion via shRNA-mediated knockdown. These results suggest that other genomic or epigenetic events, in addition to ATRX loss, are necessary for the induction of ALT in human cancer.

9 September 2017 in The Journal of Pathology
Verified
Journal Article
Open access
PDF file
JVJavier A Baena‐Del Valle
Javier A Baena‐Del Valle
QZQizhi Zheng
Qizhi Zheng
DEDavid M Esopi
David M Esopi
MRMichael Rubenstein
Michael Rubenstein
GHGretchen K Hubbard
Gretchen K Hubbard
AMAngelo M De Marzo
Angelo M De Marzo
Telomerase consists of at least two essential elements, an RNA component hTR or TERC that contains the template for telomere DNA addition and a catalytic reverse transcriptase (TERT). While expression of TERT has been considered the key rate‐limiting component for telomerase activity, increasing evidence suggests an important role for the regulation of TERC in telomere maintenance and perhaps other functions in human cancer. By using three orthogonal methods including RNAseq, RT‐qPCR, and an analytically validated chromogenic RNA in situ hybridization assay, we report consistent overexpression of TERC in prostate cancer. This overexpression occurs at the precursor stage (e.g. high‐grade prostatic intraepithelial neoplasia or PIN) and persists throughout all stages of disease progression. Levels of TERC correlate with levels of MYC (a known driver of prostate cancer) in clinical samples and we also show the following: forced reductions of MYC result in decreased TERC levels in eight cancer cell lines (prostate, lung, breast, and colorectal); forced overexpression of MYC in PCa cell lines, and in the mouse prostate, results in increased TERC levels; human TERC promoter activity is decreased after MYC silencing; and MYC occupies the TERC locus as assessed by chromatin immunoprecipitation (ChIP). Finally, we show that knockdown of TERC by siRNA results in reduced proliferation of prostate cancer cell lines. These studies indicate that TERC is consistently overexpressed in all stages of prostatic adenocarcinoma and that its expression is regulated by MYC. These findings nominate TERC as a novel prostate cancer biomarker and therapeutic target. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

3 April 2017 in Cancer Cytopathology
Verified
Journal Article
Open access
PDF file
Christopher James VandenBusscheChristopher James VandenBussche
Christopher James VandenBussche
DADerek B Allison
Derek B Allison
MGMindy K. Graham
Mindy K. Graham
VCVivek Charu
Vivek Charu
ALAnne Marie Lennon
Anne Marie Lennon
CHChristopher Heaphy
Christopher Heaphy
BACKGROUND: Pancreatic neuroendocrine tumors (PanNETs) frequently use the alternative lengthening of telomeres (ALT) pathway for telomere maintenance. ALT is strongly correlated with α thalassemia‐mental retardation, X linked (ATRX), and death domain‐associated protein 6 (DAXX) alterations and a poor prognosis in patients with primary PanNET. Because fine‐needle aspiration (FNA) is a noninvasive way to sample tumors, the authors evaluated whether they could accurately detect ALT and loss of ATRX/DAXX in a primary PanNET cohort of FNAs.METHODS: All preoperative FNA cytology cases (2005‐2016) with adequate remnant FNA cell block material were assessed for ALT by telomere‐specific fluorescence in situ hybridization and for ATRX and DAXX protein expression by immunohistochemistry. For 21 patients who underwent tumor resection, the resected specimen also was assessed to determine the concordance between the FNA and surgical specimens.RESULTS: In the primary PanNET cohort of 65 FNAs, ALT was detected in 15 specimens (23%). Although all ATRX‐negative and DAXX‐negative tumors were ALT‐positive, 3 of 14 (21%) ALT‐positive tumors did not exhibit nuclear loss of either ATRX or DAXX. The ALT‐positive tumors were associated with larger radiographic size (4.9 vs 2.4 cm, on average; P < .05) and higher grade (P < .05). Overall, there was 100% concordance in ALT status and ATRX/DAXX immunohistochemistry results between the FNA and surgical specimens.CONCLUSIONS: Both ALT and loss of ATRX/DAXX can be accurately performed on FNA specimens with adequate material. Because ALT is a fundamental mechanism of pathogenesis, the ability to determine ALT in small biospecimens has implications for the design of clinical trials. Cancer Cytopathol 2017;125:544–51. © 2017 American Cancer Society.

28 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MGMindy K. Graham
Mindy K. Graham
RWRulin Wang
Rulin Wang
RCRoshan Chikarmane
Roshan Chikarmane
BABulouere Abel
Bulouere Abel
AVAjay Vaghasia
Ajay Vaghasia
SYSrinivasan Yegnasubramanian
Srinivasan Yegnasubramanian
How prostate cancer cells and their precursors mediate changes in the tumor microenvironment (TME) to drive prostate cancer progression is unclear, in part due to the inability to longitudinally study the disease evolution in human tissues. To overcome this limitation, we perform extensive single-cell RNA-sequencing (scRNA-seq) and molecular pathology of the comparative biology between human prostate cancer and key stages in the disease evolution of a genetically engineered mouse model (GEMM) of prostate cancer. Our studies of human tissues reveal that cancer cell-intrinsic activation of MYC signaling is a common denominator across the well-known molecular and pathological heterogeneity of human prostate cancer. Cell communication network and pathway analyses in GEMMs show that MYC oncogene-expressing neoplastic cells, directly and indirectly, reprogram the TME during carcinogenesis, leading to a convergence of cell state alterations in neighboring epithelial, immune, and fibroblast cell types that parallel key findings in human prostate cancer.